CN104394879A - 表皮生长因子受体表面抗原的表位及其用途 - Google Patents

表皮生长因子受体表面抗原的表位及其用途 Download PDF

Info

Publication number
CN104394879A
CN104394879A CN201380022281.4A CN201380022281A CN104394879A CN 104394879 A CN104394879 A CN 104394879A CN 201380022281 A CN201380022281 A CN 201380022281A CN 104394879 A CN104394879 A CN 104394879A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
epitope
seq
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380022281.4A
Other languages
English (en)
Chinese (zh)
Inventor
金世镐
洪广元
张基奂
金敏洙
李美祯
元钟和
许旻奎
曹炫寿
俞知镐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Mogam Biotechnology Research Institute
Original Assignee
Green Cross Corp Japan
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Mogam Biotechnology Research Institute filed Critical Green Cross Corp Japan
Priority to CN201910572748.1A priority Critical patent/CN110317259A/zh
Publication of CN104394879A publication Critical patent/CN104394879A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
CN201380022281.4A 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途 Pending CN104394879A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910572748.1A CN110317259A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616073P 2012-03-27 2012-03-27
US61/616,073 2012-03-27
PCT/KR2013/002550 WO2013147509A1 (ko) 2012-03-27 2013-03-27 표피 성장 인자 수용체 표면 항원상의 에피토프 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910572748.1A Division CN110317259A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Publications (1)

Publication Number Publication Date
CN104394879A true CN104394879A (zh) 2015-03-04

Family

ID=49260689

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380022281.4A Pending CN104394879A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途
CN201910572748.1A Pending CN110317259A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910572748.1A Pending CN110317259A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Country Status (16)

Country Link
US (3) US20150231220A1 (enExample)
EP (1) EP2832363B1 (enExample)
JP (1) JP6209206B2 (enExample)
KR (1) KR101930019B1 (enExample)
CN (2) CN104394879A (enExample)
BR (1) BR112014024192A2 (enExample)
CA (1) CA2871111C (enExample)
CO (1) CO7160042A2 (enExample)
DK (1) DK2832363T3 (enExample)
ES (1) ES2694679T3 (enExample)
IN (1) IN2014DN08778A (enExample)
MX (1) MX356550B (enExample)
MY (1) MY168077A (enExample)
PH (1) PH12014502360A1 (enExample)
RU (1) RU2650770C2 (enExample)
WO (1) WO2013147509A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
CN115226700A (zh) * 2022-08-02 2022-10-25 江苏克诺克智能科技有限公司 一种粮面害虫诱捕器及诱捕系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US20050255555A1 (en) * 2004-02-20 2005-11-17 Johns Terrance G EGF receptor epitope peptides and uses thereof
US7449559B2 (en) * 2000-06-28 2008-11-11 Commonwealth Scientific And Industrial Research Organisation Truncated EGF receptor
US20090123937A1 (en) * 2007-10-19 2009-05-14 Freeman Daniel J Methods of selecting epidermal growth factor receptor (EGFR) binding agents
WO2011140391A2 (en) * 2010-05-05 2011-11-10 The Research Foundation Of State University Of New York Egfr-related polypeptides and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US7732157B1 (en) * 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
ES2259030T3 (es) * 2000-05-19 2006-09-16 Scancell Limited Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
RU2335507C2 (ru) * 2001-06-13 2008-10-10 Генмаб А/С Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
JP2003066677A (ja) * 2001-08-24 2003-03-05 Canon Inc カラー画像形成装置及び画像補正制御方法並びに記憶媒体
EP3037105B1 (en) * 2003-06-27 2021-03-17 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2006082515A2 (en) * 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
US20080253993A1 (en) * 2005-03-31 2008-10-16 Pharmexa A/S Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
WO2010040209A1 (en) * 2008-10-06 2010-04-15 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US7449559B2 (en) * 2000-06-28 2008-11-11 Commonwealth Scientific And Industrial Research Organisation Truncated EGF receptor
US20050255555A1 (en) * 2004-02-20 2005-11-17 Johns Terrance G EGF receptor epitope peptides and uses thereof
US20090123937A1 (en) * 2007-10-19 2009-05-14 Freeman Daniel J Methods of selecting epidermal growth factor receptor (EGFR) binding agents
WO2011140391A2 (en) * 2010-05-05 2011-11-10 The Research Foundation Of State University Of New York Egfr-related polypeptides and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
杨黎青: "《免疫学基础与病原生物学》", 30 April 2007 *
王进: "《病原生物学与免疫学》", 28 February 2007 *
龚非力: "《医学免疫学》", 31 July 2009 *

Also Published As

Publication number Publication date
JP2015519875A (ja) 2015-07-16
MX356550B (es) 2018-06-01
US20170145107A1 (en) 2017-05-25
RU2014143032A (ru) 2016-05-20
EP2832363B1 (en) 2018-09-19
MY168077A (en) 2018-10-11
CA2871111C (en) 2022-06-28
MX2014011597A (es) 2015-03-10
WO2013147509A1 (ko) 2013-10-03
KR101930019B1 (ko) 2018-12-17
EP2832363A4 (en) 2016-03-23
KR20140145583A (ko) 2014-12-23
PH12014502360B1 (en) 2015-01-12
US20190153117A1 (en) 2019-05-23
ES2694679T3 (es) 2018-12-26
CO7160042A2 (es) 2015-01-15
CA2871111A1 (en) 2013-10-03
BR112014024192A2 (pt) 2017-07-25
RU2650770C2 (ru) 2018-04-17
EP2832363A1 (en) 2015-02-04
IN2014DN08778A (enExample) 2015-05-22
CN110317259A (zh) 2019-10-11
DK2832363T3 (en) 2019-01-07
PH12014502360A1 (en) 2015-01-12
US20150231220A1 (en) 2015-08-20
JP6209206B2 (ja) 2017-10-04

Similar Documents

Publication Publication Date Title
US10221246B2 (en) Pan-HER antibody composition
EP3156421B1 (en) Pan-her antibody composition
US10626155B2 (en) IL-15 and IL-15R\alpha sushi domain based immunocytokines
ES2857500T3 (es) Anticuerpo anti-mesotelina y composición que comprende el mismo
KR101477762B1 (ko) 특이성 결합 단백질 및 용도
US10047163B2 (en) Multispecific constructs
ES2708124T3 (es) Procedimiento para preparar moléculas heteromultiméricas
US11529425B2 (en) Immunoconjugates comprising signal regulatory protein alpha
CN104098698A (zh) 一种抗cd3抗体及其制法和应用
US20190153117A1 (en) Epitopes of epidermal growth factor receptor surface antigen and use thereof
CN109879966B (zh) 基于鼠源cd19抗体的人源化设计及表达验证
CN109651509B (zh) 抗cd20的人源化单抗及其制剂
HK40013803A (en) Epitopes of epidermal growth factor receptor surface antigen and use thereof
CN109593134B (zh) 抗cd20的人源化单克隆抗体及其制剂
CN113336848B (zh) 一种抗pd-1抗体及其用途
CN118894944A (zh) 抗密蛋白双特异性抗体
CN113336847A (zh) 一种抗pd-1抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150304

RJ01 Rejection of invention patent application after publication